Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?

iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.

Zacks Investment Research • 7 hours ago

iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference

SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference.

GlobeNewsWire • Aug 26, 2026

iRhythm: The Algorithmic Margin Inflection Changes The Story

iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial inflection: 20.1% revenue growth, 72.8% gross margin, and adjusted EBITDA margin expansion to 19.3%, with raised full-year guidance and record free cash flow. The ZEUS platform's FDA clearance enables significant margin leverage, reducing clinician review time by 50% and targeting $100 million in cost savings over five years.

Seeking Alpha • Aug 21, 2026

Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Aug 17, 2026

iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform

IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.

Zacks Investment Research • Aug 14, 2026

Here's Why iRhythm Holdings, Inc. (IRTC) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 14, 2026

iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised

IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.

Zacks Investment Research • Aug 10, 2026

Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm

NEW YORK, Aug. 8, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at iRhythm caused the company to misrepresent or fail to disclose that the Zio AT monitor was a real-time monitor intended for high-risk patients.

PRNewsWire • Aug 8, 2026

iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript

iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

iRhythm Combines Strong Performance with VitalConnect Buy to Expand Remote Cardiac Care

Digital healthcare company iRhythm Holdings, Inc. (NASDAQ:IRTC) on Thursday agreed to acquire Vital Connect, Inc., a privately held developer of wearable biosensor technology.

Benzinga • Aug 7, 2026